| Species |
Human |
| Protein Construction |
IL-31 (Ser24-Thr164)
Accession # Q6EBC2 |
|
| Purity |
> 97% as analyzed by SDS-PAGE
> 97% as analyzed by HPLC |
| Endotoxin Level |
< 1 EU/μg of protein by LAL method |
| Biological Activity |
Fully biologically active when compared to standard. The specific activity is determined by inducing STAT3 activation using human U-87 MG cells. 5.0 ng/ml of rHuIL-31 can effectively induce STAT3 activation. |
| Expression System |
E. coli |
| Theoretical Molecular Weight |
15.8 kDa |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Human IL-31 is a T-cell derived cytokine that shares several structural and functional characteristics with IL-6, Oncostatin M, LIF, and Cardiotrophin-1. It signals through a receptor complex comprised of GPL (GP130-like, IL-31RA) and OSMR (Oncostatin M receptor). GPL/OSMR signaling is a strong activator of STAT3 and STAT5, and can also activate STAT1, Jak1, and Jak2 signaling pathways. IL-31 regulated immune responses have been implicated in skin physiology and inflammatory skin diseases. |
| Synonyms |
IL31; IL-31; interleukin 31 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
